AUTHOR=Marquet Pierre , Anglicheau Dany , Humeau Antoine , Adrouche Sofian , Saada Lakhdar , Bisiaux Julie , Guillemin Sara , Lardy-Cléaud Audrey , Rostaing Lionel 

TITLE=Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated

JOURNAL=Transplant International

VOLUME=Volume 37 - 2024

YEAR=2024

URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13495

DOI=10.3389/ti.2024.13495

ISSN=1432-2277

ABSTRACT=A combination of 7 factors (recipient age, end-stage renal disease, cytochrome P450 family 3 subfamily A (CYP3A) phenotype, dyslipidemia at baseline and hematocrit, total bilirubin and plasma creaCnine) explained 72.3% of tacrolimus dose-requirement in the first post-operaCve week. Together with the mulCvariate model developed, they can be leveraged to individualize tacrolimus starCng dose. Donor age, recipient age at baseline, CYP3A phenotype and corCcosteroid treatment explained 33.5% of IIV over D8-M3 post-transplant. Donor age, recipient age at baseline, CYP3A phenotype, diabetes at baseline and ASpartate Amino Transferase (ASAT) explained 36.4% of IIV at M3-M12 post-transplant.Excluding the CYP3A phenotype resulted in a significant effect of ethnicity at all Cme periods, but with lower performance to explain tacrolimus dose requirement. No significant food-effect was found at any Cme period, whether expressed as the Cming of tacrolimus intake with respect to meals, or as a fat diet.Intra-individual variability was generally moderate over M3-M12. It was significantly lower in paCents with chronic hepaCc disorder or cancer.